![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 37, 34287-34294, September 13, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, May 21, 2002
Activation of caspase-12 from procaspase-12 is
specifically induced by insult to the endoplasmic reticulum (ER)
(Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner,
B. A., and Yuan, J. (2000) Nature 403, 98-103), yet
the functional consequences of caspase-12 activation have been unclear.
We have shown that recombinant caspase-12 specifically cleaves and
activates procaspase-9 in cytosolic extracts. The activated caspase-9
catalyzes cleavage of procaspase-3, which is inhibitable by a
caspase-9-specific inhibitor. Although cytochrome c
released from mitochondria has been believed to be required for
caspase-9 activation during apoptosis (Zou, H., Henzel, W. J.,
Liu, X., Lutschg, A., and Wang, X. (1997) Cell 90, 405-413, Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997)
Cell 91, 479-489), caspase-9 as well as caspase-12 and -3 are activated in cytochrome c-free cytosols in murine
myoblast cells under ER stress. These results suggest that caspase-12
can activate caspase-9 without involvement of cytochrome c.
To examine the role of caspase-12 in the activation of downstream
caspases, we used a caspase-12-binding protein, which we identified in
a yeast two-hybrid screen, for regulation of caspase-12 activation. The
binding protein protects procaspase-12 from processing in
vitro. Stable expression of the binding protein renders
procaspase-12 insensitive to ER stress, thereby suppressing apoptosis
and the activation of caspase-9 and -3. These data suggest that
procaspase-9 is a substrate of caspase-12 and that ER stress triggers a
specific cascade involving caspase-12, -9, and -3 in a cytochrome
c-independent manner.
The caspase protease family plays a central role in the
implementation of apoptosis in vertebrates (4, 5). Caspases are
constitutively expressed in healthy cells, where they are synthesized
as precursor proteins (procaspases). Caspases are activated upon
processing of procaspases into ~20-kDa (p20) and 10-kDa (p10) mature
fragments, in addition to the N-terminal prodomain. The caspase family
is broadly divided into two groups: initiator caspases (caspase-8, -9, and -12) and effector caspases (caspase-3, -6, and -7). Initiator
caspases undergo autoprocessing for activation in response to apoptotic
stimuli. Active initiator caspases in turn process precursors of the
effector caspases responsible for dismantling cellular structures.
Recent studies have suggested the existence of a novel apoptotic
pathway in which caspase-12 functions as the initiator caspase in
response to a toxic insult to the
ER,1 such as by treatment
with tunicamycin (an inhibitor of glycosylation), thapsigargin (an
inhibitor of the ER-specific calcium ATPase), or calcium ionophores
(1). Caspase-12 is specifically activated in cells subjected to ER
stress. Furthermore, caspase-12-deficient cells are resistant to
inducers of ER stress, suggesting that caspase-12 is significant in ER
stress-induced apoptosis (1). ER stress has received growing attention
because it is considered a cause of pathologically relevant apoptosis,
and it is particularly implicated in neurodegenerative disorders (6).
However, the mechanism of caspase-12-mediated apoptosis has been
unknown, mainly due to the lack of identification of caspase-12
substrates. In this study, we have examined the susceptibility of
procaspases to active caspase-12 and have shown that procaspase-9 can
specifically be cleaved by caspase-12 in vitro.
Recent studies show that multiple death signals converge on the
mitochondrion (7). Damaged mitochondria release cytochrome c, which facilitates conformational changes in Apaf-1, the
specific activator of procaspase-9 (2, 3). The cytochrome
c·Apaf-1 complex called an apoptosome (8, 9) is thought to
recruit procaspase-9 through interaction between Apaf-1 and
procaspase-9 and facilitate autoactivation of caspase-9. Active
caspase-9 then activates caspase-3, the major effector caspase that is
responsible for destruction of various substrates (4, 5). Cytochrome c release from mitochondria has also been observed in ER
stress-induced apoptosis of several cell lines, including mouse
embryonic fibroblast cells (10, 11). The in vitro cleavage
of procaspase-9 by caspase-12 described above can be achieved in the
absence of cytochrome c, suggesting the presence of the ER
stress-specific caspase cascade, which comprises caspase-12, -9, and -3 in this order. For examination of the role of caspase-12 in activation
of the caspase cascade in vivo, however, it would be
desirable to use conditions in which cytochrome c is not
released from mitochondria; otherwise, caspase-9 could be activated by
the cytochrome c·Apaf-1 mechanism, independent of
caspase-12. We thus used a murine myoblast cell line, C2C12, to study
caspase-12, because our preliminary data showed that ER stress induces
the activation of caspase-12 and apoptosis in the cell line without the
release of cytochrome c from mitochondria. This result
suggests that cytochrome c release is not essential for ER
stress-induced apoptosis. We took advantage of the fact that cytochrome
c is not released to examine the mechanism of caspase
cascade activation in the absence of mitochondrial damage, focusing on
events that occur downstream of caspase-12 activation.
Cell Culture--
C2C12 cells (RIKEN Cell Bank, Tsukuba, Japan)
were cultured in Dulbecco's modified Eagle's medium
(Invitrogen) supplemented with 10% (v/v) fetal bovine serum
(Invitrogen), 50 units/ml penicillin, and 50 µg/ml streptomycin
(Invitrogen) at 37 °C with 5% CO2. Apoptosis was
induced in cultured cells by adding the following reagents in culture
medium unless otherwise stated: 2 µg/ml tunicamycin, 1 µM thapsigargin, and 10 µg/ml etoposide.
Examination of Mitochondrial Transmembrane
Potential--
Apoptosis was induced in C2C12 cells, and then the
cells were stained with the MitoSensor reagent
(CLONTECH) according to the manufacturer's protocol.
Preparation of S-100 from C2C12 Cells--
The C2C12 cell
100,000 × g supernatant was prepared according to the
method described in Liu and Wang (12). Briefly, cells were disrupted in
buffer containing 250 mM sucrose by a Dounce homogenizer.
The supernatant was centrifuged in a microcentrifuge for 10 min, and
subsequently at 100,000 × g for 30 min in a tabletop ultracentrifuge (Beckman Coulter, Inc.).
Western Blot Analysis--
Anti-MAGE-3 (melanoma-associated
antigen-3) polyclonal antibody was generated by immunization of rabbit
with a synthetic peptide (CHISYPPLHEWVLREGEE) as described previously
(13). Primary antibodies for Western blot analysis were used at the
following dilutions: anti-MAGE-3 polyclonal antibody, 1:400; anti-FLAG
monoclonal antibody (Sigma-Aldrich), 1:1,000; anti-hexahistidine tag
monoclonal antibody (CLONTECH), 1:5,000;
anti-caspase-12 rat monoclonal antibody (1), 1:100; anti-MAGE-3
monoclonal antibody (14), 1:2; anti-caspase-9 monoclonal antibody
(Medical and Biological Laboratories (MBL), Nagoya, Japan), 1:1,000;
anti-caspase-3 (cleaved form) antibody (Cell Signaling Technology
Inc.), 1:1,000; anti-caspase-7 monoclonal antibody (BD Biosciences),
1:250; anti-cytochrome c monoclonal antibody (BD
Biosciences), 1:500; anti- Yeast Two-hybrid Screening--
The split LexA protein system
was used for two-hybrid screening according to the method of Brent as
described by Gyuris et al. (16). The caspase-12 p10
fragment (Thr319-Asn419) was used as the bait
for the screening of a HeLa cell cDNA library. From ~2 × 107 transformants, we obtained 15 positive clones, all of
which contained sequences derived from the MAGE-3 mRNA. The 5' ends
of the cDNAs were located between codons 81 and 94. We cloned the
full-length coding region of MAGE-3 (314 amino acids) for further
analysis by polymerase chain reaction amplification of a human testis
cDNA library (CLONTECH).
Transient Transfection and
Immunoprecipitation--
Immunoprecipitation was performed after COS-1
cells (1.8 × 105 seed cells) were transfected with 5 µg of DNA. At 2 days post-transfection, cells were lysed at 0 °C
in phosphate-buffered saline containing 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% sodium lauryl sulfate, and a COMPLETE protease
inhibitor mixture (Roche Molecular Biochemicals). Cell lysates were
incubated with 30 µl of anti-FLAG (M2) affinity resin (Sigma-Aldrich)
for 4-5 h at 0 °C. Proteins that bound the affinity resin were
analyzed by Western blotting.
Protein Production--
Caspase-12- or MAGE-3 cDNA was
cloned into the vector pRSET (Invitrogen) and used for transformation
of BL21(DE3) pLysS cells. The histidine-tagged proteins synthesized in
Escherichia coli were purified on a Probond Ni-column resin
(Invitrogen). The glutathione S-transferase (GST)-MAGE-3
fusion was generated by inserting MAGE-3 cDNA into a pGEX-4T-3
vector (Amersham Biosciences). GST-MAGE-3 was purified from E. coli lysates by batch-chromatography with glutathione Sepharose-4B
beads (Amersham Biosciences).
GST Fusion Protein Pull-down Assay--
GST-MAGE-3 protein (1 µg) and histidine-tagged caspase-12 (0.1 µg) were incubated with 10 µl of glutathione Sepharose-4B beads (Amersham Biosciences) for
1 h at room temperature in 150 µl of 20 mM phosphate
buffer, pH 7.0, containing 200 mM NaCl and 0.02% Triton
X-100. Anti-hexahistidine monoclonal antibody
(CLONTECH) was used for the detection of caspase-12
p20. Proteins that bound glutathione resin were analyzed by Western blotting.
In Vitro Cleavage of Radiolabeled Procaspases--
In
vitro synthesis of 35S-labeled proteins and their
detection by autoradiography were achieved as described previously
(15). For mutant analysis, mutations at specific aspartic acid residues in procaspases were introduced by the QuikChange Site-Directed Mutagenesis Kit (Stratagene). Introduction of mutation was confirmed by
DNA sequencing. 35S-labeled procaspase (0.2 µl of the
labeled protein solution) was incubated for a cleavage assay at
37 °C with caspase-12 (0.28 µg) for 4 h. Resistance of
procaspase-12 to cleavage by active caspase-12 was examined by addition
of recombinant MAGE-3 to the procaspase-12 cleavage assay solution.
Procaspase-12 whose active site Cys residue had been replaced with Ser
was synthesized in vitro in the presence of
[35S]methionine. 35S-Labeled mutant
procaspase-12 (0.2 µl of the labeled protein solution) was incubated
with active caspase-12 (0.28 µg) for 45 min in the presence or
absence of MAGE-3.
In Vitro Activation of Caspase-9 in S-100 by
Caspase-12--
Cytochrome c-free cytosol from C2C12 cells
(10 µg of proteins) was treated with recombinant caspase-12 p30 (0.8 µg) at 37 °C for 4 h. Activation of caspase-9 and -3 was
examined by Western blot analysis. Five micrograms of proteins were
loaded on each lane. As a positive control for caspase-9 activation,
the cytochrome c-free cytosol was incubated with 10 µM bovine cytochrome c (Sigma-Aldrich) and 1 mM dATP for 60 min at 37 °C. For inhibition of caspase-9 activity, LEHD-fluoromethylketone (BioVision, Palo Alto, CA) was added to the cytosol before the addition of caspase-12.
Stable Cell Lines--
MAGE-3 stable cell lines of C2C12 were
generated as follows. MAGE-3 cDNA was cloned into pcDNA3.1( Indirect Immunofluorescence Microscopy--
Cells were fixed in
4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Cells
were incubated with either anti-caspase-12 monoclonal (1) or
anti-MAGE-3 polyclonal antibody (this study). Primary antibodies were
detected with either Alexa594-coujugated anti-rabbit IgG antibody
(1:500) or a combination of biotin-labeled anti-rat IgG antibodies
(1:500) and Alexa488-coujugated avidin (1:1,000). These reagents were
obtained from Molecular Probes. Images were captured with a cooled
charge-coupled device camera mounted on an Olympus IX70 microscope.
Procaspase-9 Is a Substrate of Caspase-12--
We examined how
caspase-12 processing is linked to the activation of other caspases.
For an in vitro cleavage assay, we produced recombinant
caspase-12 (p30) whose N-terminal prodomain had been removed and
replaced with a hexahistidine tag. The p30 protein undergoes efficient
autoprocessing into p20 and p10 peptides when overexpressed in E. coli (p30* in Fig. 1A). A
mutant p30 (p30C/S), whose active site Cys is substituted with Ser, is
not processed in E. coli (Fig. 1A). The mature
caspase-12 (p30*) exhibits proteolytic activity and cleaves
procaspase-12 into 35- and 12-kDa fragments (Fig. 1B,
lane 16). The cleavage site was located at Asp318, because a
procaspase-12 mutant in which Asp318 was replaced with Ser was resistant to caspase-12 digestion (data not shown). Asp318 is also the
cleavage site for autoprocessing in E. coli (Fig.
1A), as revealed by amino acid sequencing of p10 by the
Edman degradation method (data not shown). p30* cleaves caspase-9 (Fig.
1, B and C) but not other caspase precursors
(murine caspase-1 and -2, and human caspase-3, -6, and -8) under the
experimental conditions. Note that processing site sequences between
p20 and p10 are highly conserved between murine and human caspase-3,
-6, -7, and -8. Mutation analysis of caspase-9 (Fig. 1C)
indicates that caspase-12 cleaves at specific Asp residues in the
linker region between p20 and p10 in the procaspase-9 polypeptide
(LDSD349 and SEPD353 in the murine caspase-9, PEPD315 in the human
caspase-9). Asp353 of the murine caspase-9 and
Asp315 of human caspase-9 have been reported to be the
cleavage sites for the activation of procaspase-9 (17, 18). The
caspase-9 cleavage observed in vitro thus suggests the
possibility that caspase-9 can be activated by caspase-12 during ER
stress-induced apoptosis. Under the experimental conditions used,
murine caspase-9 contains another cleavage site(s) for caspase-12
in vitro, cleavage at which generates 27- and 20-kDa
fragments. We did not further analyze these additional cleavage site(s)
because we could detect neither 27- nor 20-kDa caspase-9 fragments in
apoptotic cells (described below; data not shown). Procaspase-7 seems
to be only slightly processed by active caspase-12 (Fig. 1B,
lane 10). The in vitro cleavage of procaspase-7
was not studied further because processing of procaspase-7 is
undetectable in C2C12 cells subjected to ER stress (Fig.
1D).
Cytochrome c Is Not Essential for ER Stress-induced Caspase
Activation--
Several reports have demonstrated that ER stress
causes mitochondrial damage, which results in cytochrome c
release from mitochondria (e.g., Refs. 10, 11). Cytochrome
c in cytosol and Apaf-1 can induce activation of caspase-9
(2, 3). To examine whether there is an ER stress-specific caspase
cascade that is initiated by caspase-12, we used a murine myoblast cell
line, C2C12, because this cell line undergoes ER stress-induced
apoptosis without cytochrome c release from mitochondria.
Cytosolic extracts (S-100) of tunicamycin- or thapsigargin-treated
C2C12 cells contain cytochrome c at the same level as that
detected in S-100 fractions prepared from untreated cells (Fig.
2A). Nevertheless, more than
50% of the cells undergo apoptosis (see below). Cytochrome
c release per se, however, is functional in C2C12
cells, because treatment of C2C12 cells with etoposide or serum
deprivation induces apoptosis at a similar level of lethality and with
a significant release of cytochrome c. After apoptosis was
induced by ER stress inducers, the mitochondrial transmembrane
potential was maintained in apoptotic cells (small cells with condensed
nuclei), as in the case of untreated cells, which was exhibited by
mitochondrial accumulation of fluorochromes and their conversion to
emit the orange color (Fig. 2B). Etoposide-treatment of
C2C12 cells resulted in decrease in mitochondrial transmembrane potential, which was monitored by the green color of the fluorochromes in the cytosol (Fig. 2B). These results suggest that
mitochondria in C2C12 cells do not suffer severe damages from ER
stress, thus releasing little cytochrome c into cytosol.
Treatment of C2C12 cells with ER stress inducers, either tunicamycin or
thapsigargin, results in the processing of procaspase-12 (48 kDa, Fig.
2C) and apoptosis. A 35-kDa fragment was detected by
antibodies specific to the p20 region (1). Caspase-9 and caspase-3 are
also activated in C2C12 cells treated with ER stress inducers (Fig.
2C). The activation of caspase-3, one of the most downstream
caspases, suggests that the ER stress-specific caspase cascade
comprises caspase-12, -9, and -3. It has been suggested that calpain is
involved in activation of caspases in cultured glial cells after
deprivation of oxygen and glucose (19). In the apoptotic C2C12 cells,
however, cleavage of a calpain substrate, Bcl-XL, was not detected
(Fig. 2C), suggesting that caspase activation in C2C12 cells
treated with ER stress inducers is independent of calpain.
Direct Activation of Caspase-9 by Caspase-12--
We then examined
whether caspase-9 activation occurs by the cleavage of procaspase-9 by
active caspase-12 without the release of cytochrome c in
cell extracts. Incubation of the S-100 fraction of untreated C2C12
cells with active caspase-12 results in a pattern of cleavage of
procaspase-9 that is similar to that observed in S-100 of apoptotic
C2C12 cells, the cleavage products being a doublet of 35-kDa fragments
(Fig. 3A, lanes 2 and 4). A control experiment showed that addition of
cytochrome c and dATP to S-100 of untreated cells also
caused processing of procaspase-9 into 35-kDa fragments that appeared
as a doublet on the blot (Fig. 3B, lane 3). The
lower band was less intense than the upper band in the case of
caspase-12-induced processing (Fig. 3B, lane 2) and the apoptotic S-100 fractions (lane 4). The ratio of
these 35-kDa fragments was different from that observed in the
cytochrome c-treated S-100 (Fig. 3B, lane
3). It remains to be revealed whether the difference in the ratio
of these fragments reflects a difference in mechanism of
processing.
The cleavage of procaspase-9 is not suppressed in the presence of a
caspase-9-specific inhibitor LEHD-fluoromethylketone (20), indicating that procaspase-9 is cleaved by active caspase-12, independent of the inherent autoprocessing activity of procaspase-9 (Fig. 3B, upper panel, lane 4). We
then examined caspase-9 activation through detection of specific
cleavage at Asp175 within the procaspase-3 polypeptide, the downstream
target of caspase-9 (3). Incubation of the S-100 fraction with
caspase-12 causes processing of caspase-3 at Asp175 of ITED175 (Fig.
3B, lower panel, lane 3), suggesting that the activated caspase-9 in the S-100 fraction cleaved
procaspase-3. The specific cleavage of procaspase-3, but not
procaspase-9, can be inhibited by LEHD-fluoromethylketone, (Fig.
3B, lane 4). This result indicates that cleavage
of procaspase-3 is dependent on caspase-9, as already observed for
apoptosis induced by various stimuli other than ER stress (3,
21-23).
Suppression of Procaspase-12 Processing by Its Binding
Protein--
We have recently isolated by yeast two-hybrid screening
from a HeLa cell cDNA library a human cancer antigen, MAGE-3, as a protein that specifically binds the caspase-12 p10 fragment (see "Experimental Procedures"). Because MAGE-3 can suppress the
activity of procaspase-12, as described below, we used the protein to
examine the significance of caspase-12 activation in ER stress-induced apoptosis in C2C12 cells. MAGE-3 is a member of the
MAGE gene family and is expressed in various types of
tumor but not in normal tissues except for the testis (24). Although
the specific interaction between caspase-12 and MAGE-3 is intriguing,
it remains unclear whether MAGE-3 plays any role in caspase regulation
in human cells (see "Discussion"). MAGE-3 does not bind to other
caspases, such as caspase-9 (of either murine or human origin), as
tested by the two-hybrid assay (results of murine caspase-1, -9, and
-11 and human caspase-3, -6, and -7 are shown in Fig.
4A).
The MAGE-3 protein can also bind both the caspase-12 p10 fragment and
procaspase-12 in mammalian cells. When MAGE-3 is expressed in COS-1
cells by transient transfection it can be co-precipitated with
FLAG-tagged p10 (Fig. 4B, lane 3) or FLAG-tagged
procaspase-12 (lane 7) using an anti-FLAG antibody. MAGE-3
was not co-precipitated with FLAG-tagged p10 fragments of murine
caspase-2 and human caspase-8, whose binding ability could not be
examined by the two-hybrid assay because of significant background
activity (data not shown). Fig. 4C shows that p30C/S
(unprocessed p30) co-precipitates with GST-tagged MAGE-3 (lanes
3 and 4). Under the same conditions, however, p30*
(processed) is not efficiently co-precipitated by GST-MAGE-3 (Fig.
4C, lanes 1 and 2), suggesting that
MAGE-3 does not efficiently bind the p10 fragment in active
caspase-12. It is possible that the p10 fragment within mature
caspase-12 is not fully accessible to MAGE-3 because of steric
hindrance by the p20 portion. X-ray crystallographic analyses of
caspase-1 and caspase-3 have suggested that they undergo a
conformational change upon maturation (25-27). This conformational
change may occur in caspase-12 and result in the p10 fragment being
less exposed for binding to MAGE-3.
Consistent with the binding of MAGE-3 to unprocessed caspase-12, MAGE-3
protects procaspase-12 from cleavage by active p30* in a
dose-dependent manner (Fig. 4D, lanes
2-7). Substitution of MAGE-3 with bovine serum albumin fails to
inhibit cleavage (Fig. 4D, lane 9). It is less
likely that MAGE-3 blocks active caspase-12 by acting as a competitive
inhibitor. In Fig. 4D, lane 7, small amounts of
the 35- and 12-kDa fragments can be detected, indicating the presence
of caspase-12 activity. Under such conditions, excessive levels of
active caspase-12 are expected to be protected from inhibition by
MAGE-3. However, an enhancement of cleavage was not detected in the
presence of 4-fold higher levels of caspase-12 (lane 8). In
contrast, when twice as much substrate is added to the reaction mixture
in the presence of MAGE-3, both p35 and p12 cleavage products are
produced at the same levels as in the absence of MAGE-3 (Fig.
4E, lane 2). It is more likely that MAGE-3
protects procaspase-12 from processing by specifically binding the p10 portion of the precursor. This result is consistent with our
observation that the affinity of MAGE-3 for p30C/S is much higher than
that for active caspase-12 (Fig. 4C).
Suppression of Caspase-12 Activation Resulted in Suppression of
Caspase-9 Activation and Apoptosis in Vivo--
To examine the
involvement of caspase-12 in the activation of the caspase cascade, we
established stable transfectants (C2C12/MA21) of C2C12 cells that
overexpress MAGE-3 (Fig. 5A).
Colocalization of MAGE-3 with endogenous caspase-12, an ER-associated
protein (1), in C2C12/MA21 was observed by double immunostaining (Fig. 5B), although signals of free MAGE-3 proteins (red color)
were still evident in the merged image. This observation was supported by a cell fractionation experiment, where MAGE-3 was detected in the
microsomal fraction as well as in S-100 (Fig. 5C). Treatment of either parental C2C12 cells or a vector control line (C2C12/vec2) with ER stress inducers leads to morphological changes typical of
apoptosis. Over 50% of C2C12/vec2 cells exhibit apoptotic morphology after 24 h treatment with tunicamycin or thapsigargin, as
indicated by the small round shape of the cells (Fig. 5D).
The nuclei of these round cells are fully condensed, as visualized by
staining with Hoechst 33342 (data not shown). However, C2C12/MA21 cells undergo apoptosis at the same low background level (< 5%) observed in
untreated cells under the same conditions (Fig. 5D).
Activation of caspase-12 is almost completely suppressed in C2C12/MA21
cells treated with ER stress inducers (Fig. 5E). Processing
of caspase-9 and caspase-3 also does not take place in MAGE-3
overexpressing cells. Both C2C12/MA21 cells and C2C12/vec2 cells
respond to ER stress and elicit the unfolded protein response (reviewed
in Ref. 28), as demonstrated by the induction of BiP, an ER-specific heat shock protein (Fig. 5F). These data indicate that
MAGE-3 overexpression renders cells resistant to ER stress by
suppressing the activation of caspase-12. Therefore, caspase-12 is a
critical component of the apoptotic machinery that responds to ER
stress, confirming the previous observation (1) that caspase-12 null mice are resistant to the toxic effects of ER stress (e.g.,
intraperitoneal injection of tunicamycin). Furthermore, concomitant
inhibition of the activation of other caspases (caspase-9 and -3) in
stably transfected C2C12/MA21 cells strongly suggests that caspase-9 and -3 are located downstream of caspase-12 in the ER stress-specific caspase cascade. These results suggest that procaspse-9 is a substrate of caspase-12 in vivo as well as in vitro. Both
C2C12/MA21 and C2C12/vec2 cells undergo apoptosis when treated with
staurosporine, a protein kinase inhibitor (data not shown), indicating
that the apoptotic machinery per se is functional. This
result supports the idea that the suppressive effect of MAGE-3 is
specific for the ER stress-induced apoptotic pathway mediated by
caspase-12.
Our data suggest the following: 1) caspase-12 activation triggers
the caspase cascade in response to ER stress; 2) procaspase-9 is a
substrate of caspase-12 and caspase-9 activation can be achieved in
cells without the release of cytochrome c from
mitochondria; and 3) proteolytic signals in the cascade are transmitted
from caspase-12 to an effector caspase (caspase-3) via
caspase-9 (Fig. 6). An Apaf-1/cytochrome
c-independent mechanism of caspase-9 activation has recently
been reported for dexamethasone-induced apoptosis of multiple myeloma
cells (29). Because recombinant caspase-9 prepared from E. coli exhibits protease activity (30), it is obvious that Apaf-1
(and cytochrome c) is not essential for the activation of
caspase-9. However, the lack of cytochrome c release in
C2C12 cells does not exclude the possibility that Apaf-1/cytochrome
c is involved in other cell lines. Cytochrome c
release has been observed in both mouse and rat embryonic fibroblast cells subjected to ER stress (10, 11). It is likely that caspase-9 activation can be achieved by caspase-12-dependent
cleavage, by an Apaf-1/cytochrome c mechanism, or by both
means (Fig. 6). A similarly complex mechanism by which apoptosis is
triggered has been described previously for the death receptor mediated
pathway (31). Stimulation of death receptors (e.g., Fas)
results in the activation of caspase-8, which in turn activates
effector caspases in a direct manner. Alternatively, caspase-8 may
cleave Bid, a pro-apoptotic member of the Bcl-2 family, and the cleaved Bid may in turn induce cytochrome c release through
mitochondrial damage (32, 33). Our studies present another example of
redundancy in the mechanisms by which apoptosis is executed. It is
unclear, then, how cytochrome c release is induced by ER
stress in cell lines other than C2C12 cells. ER stress induces
cytochrome c release in rat fibroblast cells in a caspase-8-
and Bid-independent manner (11). Possible mediators linking the ER to
mitochondria, as suggested by recent studies, include the c-Abl
tyrosine kinase (10) and calcium (34). The present study reveals that
C2C12 cells are useful for the study of the ER stress-specific caspase cascade because a simpler mechanism probably operates in these cells.
Comparison of C2C12 cells with other cell lines would contribute to the
dissection of the mechanism of ER stress-induced apoptosis.
To conclude that caspase-12 initiates the ER-specific caspase cascade
in a direct manner, it should be critical to show that caspase-12
cleaves procaspase-9 at the processing site for activation, and the
cleavage product (caspase-9) is active. We have demonstrated the
specific cleavage and activation of procaspase-9 by purified caspase-12. Furthermore, we have shown direct correlation between suppression of caspase-12 activation and suppression of caspase-9 activation (and apoptosis) in vivo using the caspase-12
binding protein. These data strongly suggest that caspase-12, activated in response to ER stress, cleaves procaspase-9 to initiate the ER
stress specific caspase cascade. During preparation of this article,
Ellerby's group reported that Apaf-1 In this study, we also identify MAGE-3 as a protein that specifically
binds procaspase-12. MAGE-3 has been detected in tumor cell lines,
including melanoma cell lines (24). Because the precise human ortholog
of murine caspase-12 is not yet known (36), it remains unclear whether
MAGE-3 plays any role in caspase regulation in human cells. Our
preliminary data show that endogenous MAGE-3 is detected in the
microsomal fraction as well as in the S-100 fraction in several human
tumor cell lines so far examined (e.g., Jurkat, HeLa),
although the abundance in the microsomal fraction depends on cell lines
(data not shown). Our results also show that overexpression of
antisense MAGE-3 rendered Jurkat cells less resistant to ER stress
induced by A23187, whereas the sense construct did not affect the
resistance of Jurkat cells (data not shown). These results support the
theory that specific expression of MAGE-3 in tumor cells may be
involved in resistance of tumor cells to ER stress. It is interesting
to note that MAGE-3 is more often expressed by metastatic melanomas
than primary tumors (24). Although the involvement of MAGE-3 in
resistance to ER stress has not been studied in detail, a correlation
between malignancy and resistance to thapsigargin is evident in human
melanoma cells (37, 38). These observations together suggest the
possibility that MAGE-3 may regulate the human caspase-12 ortholog. We
have shown that murine caspase-12 can cleave procaspse-9 of both murine and human origins, although their cleavage site sequences are not
identical (Fig. 1C). It is interesting to note that the
processing sites within procaspase-9 of both origins are functionally
conserved so that they can be cleaved by caspase-12, implying the
presence of a functional homolog of caspase-12 in human cells.
Prolonged ER stress contributes to cell death and is linked to the
pathogenesis of several different neurodegenerative disorders (39). It
is possible that suppression of caspase-12 activation per se
generates little toxicity in mammalian bodies, because caspase-12 null
mutant mice do not show abnormalities during either development or
adulthood (1). Therefore, a study of the specific interactions between
MAGE-3 and procaspase-12 may provide a basis for the development of
therapeutic reagents against unwanted activation of caspases caused by
ER stress.
We thank J. Yuan and T. Nakagawa for
anti-caspase-12 monoclonal antibody; G. Spagnoli for anti-MAGE-3
monoclonal antibody; R. Takahashi for human caspase-6, -7, and -9
cDNAs; M. Chijimatsu and K. Takio for amino acid sequencing; and Y. Ichikawa and R. Nakazawa for DNA sequencing.
*
This work was supported in part by a grant from the
Bioarchitect Research Project of RIKEN and a President's Special
Research Grant of RIKEN (to N. M.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.:
81-48-467-9538; Fax: 81-48-462-4671; E-mail:
morishim@postman.riken.go.jp.
**
Present address: Graduate School of Biological Sciences, University
of Tokyo, 7-3-1 Hongo, Tokyo 113-8654, Japan.
Published, JBC Papers in Press, July 3, 2002, DOI 10.1074/jbc.M204973200
The abbreviations used are:
ER, endoplasmic
reticulum;
GST, glutathione S-transferase.
An Endoplasmic Reticulum Stress-specific Caspase Cascade in
Apoptosis
CYTOCHROME c-INDEPENDENT ACTIVATION OF CASPASE-9 BY
CASPASE-12*
§¶,
§
,
,
Bioarchitect Research Group and
§ Cellular and Molecular Biology Laboratory, RIKEN (The
Institute of Physical and Chemical Research), 2-1 Hirosawa, Wako,
Saitama 351-0198, Japan, and the
Department of Biological
and Environmental Sciences, Faculty of Science and Engineering, Saitama
University, 255 Shimo-Ohkubo, Saitama 338-8570, Japan
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-tubulin monoclonal antibody (Oncogene
Science), 1:1,000; anti-BiP monoclonal antibody (BD Biosciences),
1:500. Primary antibodies on Western blots were detected as described
previously (15).
)
vector (Invitrogen). The plasmid DNA was linearized by ScaI
digestion before transfection. Transfection was performed with a
Superfect transfection reagent (QIAGEN) according to the
manufacturer's protocol. MAGE-3 cDNA cloned into the
pcDNA3.1(
) vector (Invitrogen) was used for stable transfection.
Stable transfectants were grown in medium containing 600 µg/ml G418
(Invitrogen) for 2 weeks before cloning.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (65K):
[in a new window]
Fig. 1.
Procaspase-9 is a substrate of caspase-12.
A, purification of the caspase-12 p30 protein overexpressed
in E. coli. Either wild-type p30* or the inactive mutant
(C/S) protein was tagged with hexahistidine at the N terminus and
purified by Ni-column affinity chromatography. Proteins were detected
by Coomassie Brilliant Blue staining. B, procaspase-9 and
procaspase-12 are specifically cleaved by active caspase-12.
35S-Labeled procaspases were incubated with (+) or without
(
) active caspase-12 at 37 °C for 4 h and analyzed by
SDS-polyacrylamide gel electrophoresis as described previously (15).
Arrowheads indicate cleavage products. C,
cleavage sites within procaspase-9 are processing sites for activation.
Mutation of specific Asp residues (Asp-349 and Asp-353 in murine
procaspase-9 and Asp-315 in human procaspase-9, respectively)
significantly reduces cleavage by caspase-12 (+). Arrowheads
indicate cleavage fragments. D, caspase-7 is not activated
in C2C12 cells under ER stress (TG, thapsigargin;
TUN, tunicamycin). The Western blot was probed with an
anti-caspase-7 monoclonal antibody.

View larger version (27K):
[in a new window]
Fig. 2.
Caspase activation in C2C12 occurs
independently of cytochrome c release. A,
cytochrome c is not released in the cytosol of C2C12 cells
treated with ER stress inducers. S-100 fractions of C2C12 cells after
treatment with various apoptotic stimuli were immunoblotted and probed
with antibody to cytochrome c. Actively growing C2C12 cells
were treated with 2 µg/ml tunicamycin (TUN), 1 µM thapsigargin (TG) for 24 hr, or 100 µg/ml
etoposide for 48 h or subjected to serum deprivation for 48 h. UT, untreated cells. B, integrity of
mitochondrial transmembrane potential during ER stress-induced
apoptosis in C2C12. Cells were treated with either tunicamycin,
thapsigargin, or etoposide and examined for mitochondrial transmembrane
potential using the MitoSensor reagent (CLONTECH).
Apoptotic cells are indicated by arrowheads. Intact
mitochondria were stained in orange, whereas apoptotic cells
containing damaged mitochondrial membrane is visualized by
green fluorochrome in cytosols. C, caspase
activation in apoptotic C2C12 cells. C2C12 cells were treated with
either tunicamycin or thapsigargin for 24 h. Arrowheads
indicate procaspases (pro) and their cleavage
fragments.

View larger version (15K):
[in a new window]
Fig. 3.
Activation of caspase-9 by caspase-12.
A, caspase-9 cleavage by caspase-12. Caspase-9 in S-100
fractions was detected on a Western blot using anti-caspase-9 antibody.
Lane 1, untreated S-100 prepared from C2C12 cells;
lane 2, S-100 fractions treated with active caspase-12;
lane 3, addition of cytochrome c and dATP to the
S-100 fraction; lane 4, S-100 fraction prepared from
tunicamycin-treated C2C12 cells. B, activation of the ER
stress-specific caspase cascade in vitro. Incubation of
S-100 fractions prepared from C2C12 cells with active caspase-12
results in the activation of the ER stress-specific caspase cascade
in vitro. Lane 1, S-100 fractions were directly
subjected to SDS-polyacrylamide gel electrophoresis without incubation.
Lanes 2-4, S-100 was incubated at 37 °C for 4 h
with or without reagents indicated in the figure. The Western blot was
probed with anti-caspase-9 or anti-caspase-3 (cleaved form) antibody.
An asterisk indicates a protein that nonspecifically reacts
to the anti-caspase-3 antibody.

View larger version (62K):
[in a new window]
Fig. 4.
A caspase-12 binding protein suppresses
processing of procaspase-9. A, MAGE-3 binds to
caspase-12 p10 but not to other caspases (p10) in the yeast two-hybrid
system. Positive control (P), the active Gal4 transcription
factor; negative control (N), empty vector. B,
MAGE-3 binds to caspase-12 p10 in cells. Cell lysates were prepared
from COS-1 cells transfected with plasmids bearing MAGE-3 (lanes
1-8) or FLAG-tagged caspase-12 (procaspase-12, lanes 1 and 3; caspase-12 p10, lanes 5 and
7), and proteins were precipitated using the anti-FLAG
affinity gel. Lanes 2, 4, 6, and
8, a vector control for FLAG-caspase-12. MAGE-3 proteins
were detected by Western blot analysis with an anti-MAGE-3 rabbit
polyclonal antibody. C, coprecipitation of the GST-MAGE-3
fusion protein with an unprocessed form of caspase-12 (p30C/S).
Lanes 1 and 2, p30*; lanes 3 and
4, p30C/S. Lanes 1 and 3, GST control;
lanes 2 and 4, GST-MAGE-3. D,
procaspase-12 bound to MAGE-3 is resistant to cleavage by active
caspase-12. 35S-Labeled procaspase-12 was prepared by
in vitro transcription and translation (15). Lane
1, intact procaspase-12; lanes 2-7, procaspase-12
incubated with active caspase-12 (0.28 µg) and purified MAGE-3. The
amounts of MAGE-3 included in the reaction mixture were: 0 µg
(lane 2), 0.3 µg (lane 3), 1.5 µg (lane
4), 3 µg (lane 5), 6 µg (lane 6), and 12 µg (lane 7). Lane 8, procaspase-12 incubated
with active caspase-12 (1.1 µg) and 12 µg of MAGE-3. Lane
9, procaspase-12 incubated with active caspase-12 (0.28 µg) and
12 µg of bovine serum albumin. E, production of cleaved
fragments in the presence of excess substrate. Procaspase-12 was
incubated with active caspase-12 (0.28 µg) and 12 µg of MAGE-3. The
amount of labeled protein used for digestion was 0.2 µl (lane
1) and 0.4 µl (lane 2). Lane 3, 12 µg of
bovine serum albumin was substituted for MAGE-3 in the reaction
mixture.

View larger version (39K):
[in a new window]
Fig. 5.
Suppression of caspase-12 activation renders
cells resistant to ER stress. A, stable expression of MAGE-3 in
C2C12 cells. Cell lysates were probed with an anti-MAGE-3 monoclonal
antibody (14). Lane 1, vector control (C2C12/vec2);
lane 2, C2C12/MA21. B, Colocalization of
caspase-12 and MAGE-3 in C2C12/MA21 cells detected by an anti-MAGE-3
rabbit polyclonal antibody and an anti-caspase-12 rat monoclonal
antibody. Primary antibodies were detected with either
Alexa594-coujugated anti-rabbit IgG antibody or a combination of
biotin-labeled anti-rat IgG antibodies and Alexa488-conjugated avidin.
C, intracellular localization of ectopically expressed MAGE-3. Either
C2C12/MA21 or the vector control cell was fractionated into S-100
(S) and the microsomal fraction (M). 25 µg of
proteins were loaded on each lane and examined by Western blot analysis
by using the anti-MAGE-3 monoclonal antibody. D, morphology
of C2C12/vec2 (top) and C2C12/MA21 (bottom) cells after a 1-day
treatment with 2 µg/ml tunicamycin (TUN) or 1 µM thapsigargin (TG). UT, untreated
cells. E, suppression of caspase-12 activation in stable
cell lines. Stable C2C12/vec2 and C2C12/MA21 transfectants were
incubated with 2 µg/ml tunicamycin or 1 µM
thapsigarigin. Cell extracts from these cell lines were analyzed by
Western blot analysis. Arrowheads indicate caspase cleavage
fragments. F, ER stress elicited the unfolded response in
the MAGE-3 overexpressing cells. Cell lysates were probed with either
anti-BiP antibody or anti-
-tubulin antibody.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (27K):
[in a new window]
Fig. 6.
Model of ER stress-induced caspase
activation. See text for details.
/
knockout cells undergo ER
stress-induced apoptosis (35). This result indicates that the
cytochrome c·Apaf-1 complex is not essential for apoptosis induced by ER stress. They also showed that transient overexpression of
a catalytic mutant of caspase-12 results in partial resistance of the
knockout cells to ER stress and demonstrated that procaspase-9 can be
cleaved by microsomal fractions, although the cleavage site has not
been determined. These data are consistent with our findings described
above in terms of the dependence of caspase-9 activation on
caspase-12.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Nakagawa, T.,
Zhu, H.,
Morishima, N., Li, E., Xu, J.,
Yankner, B. A.,
and Yuan, J.
(2000)
Nature
403,
98-103[CrossRef][Medline]
[Order article via Infotrieve]
2.
Zou, H.,
Henzel, W. J.,
Liu, X.,
Lutschg, A.,
and Wang, X.
(1997)
Cell
90,
405-413[CrossRef][Medline]
[Order article via Infotrieve]
3.
Li, P.,
Nijhawan, D.,
Budihardjo, I.,
Srinivasula, S. M.,
Ahmad, M.,
Alnemri, E. S.,
and Wang, X.
(1997)
Cell
91,
479-489[CrossRef][Medline]
[Order article via Infotrieve]
4.
Thornberry, N. A.,
and Lazebnik, Y.
(1998)
Science (Wash. D. C.)
281,
1312-1316 5.
Cryns, V. L.,
and Yuan, J.
(1998)
Genes Dev.
12,
1551-1570 6.
Aridor, M.,
and Balch, W. E.
(1999)
Nat. Med.
5,
745-751[CrossRef][Medline]
[Order article via Infotrieve]
7.
Wei, M. C.,
Zong, W.-X.,
Cheng, E. H.-Y.,
Lindsten, T.,
Panoutsakopoulou, V.,
Ross, A. J.,
Roth, K. A.,
MacGregor, G. R.,
Thompson, C. B.,
and Korsmeyer, S. J.
(2001)
Science (Wash. D. C.)
292,
727-730 8.
Zhou, Q., Li, Y.,
Liu, X.,
and Wang, X.
(1999)
J. Biol. Chem.
274,
11549-11556 9.
Saleh, A.,
Srinivasula, S. M.,
Acharya, S.,
Fishel, R.,
and Alnemri, E. S.
(1999)
J. Biol. Chem.
274,
17941-17945 10.
Ito, Y.,
Mishra, N.,
Kumar, S.,
Narula, N.,
Kharbanda, S.,
Saxena, S.,
and Kufe, D.
(2001)
Mol. Cell. Biol.
21,
6233-6242 11.
Häcki, J.,
Egger, L.,
Monney, L.,
Conus, S., T., R.,
Fellay, I.,
and Borner, C.
(2000)
Oncogene
19,
2286-2295[CrossRef][Medline]
[Order article via Infotrieve]
12.
Liu, X.,
and Wang, X.
(2000)
Methods Enzymol.
322,
177-182[Medline]
[Order article via Infotrieve]
13.
Nakanishi, K.,
Maruyama, M.,
Shibata, T.,
and Morishima, N.
(2001)
J. Biol. Chem.
276,
41237-41244 14.
Kocher, T.,
Schultz-Thater, E.,
Gudat, F.,
Schaefer, C.,
Casorati, G.,
Juretic, A.,
Willimann, T.,
Harder, F.,
Heberer, M.,
and Spagnoli, G. C.
(1995)
Cancer Res.
55,
2236-2239 15.
Morishima, N.
(1999)
Genes Cells
4,
401-414[Abstract]
16.
Gyuris, J.,
Golemis, E.,
Chertkov, H.,
and Brent, R.
(1993)
Cell
75,
791-803[CrossRef][Medline]
[Order article via Infotrieve]
17.
Srinivasula, S. M.,
Ahmad, M.,
Fernandes-Alnemri, T.,
and Alnemri, E. S.
(1998)
Mol. Cell
1,
949-957[CrossRef][Medline]
[Order article via Infotrieve]
18.
Fujita, E.,
Egashira, J.,
Urase, K.,
Kuida, K.,
and Momoi, T.
(2001)
Cell Death Differ.
8,
335-344[CrossRef][Medline]
[Order article via Infotrieve]
19.
Nakagawa, T.,
and Yuan, J.
(2000)
J. Cell Biol.
150,
887-894 20.
Thornberry, N. A.,
Rano, T. A.,
Peterson, E. P.,
Rasper, D. M.,
Timkey, T.,
Garcia-Calvo, M.,
Houtzager, V. M.,
Nordstrom, P. A.,
Roy, S.,
Vaillancourt, J. P.,
Chapman, K. T.,
and Nicholson, D. W.
(1997)
J. Biol. Chem.
272,
17907-17911 21.
Bossy-Wetzel, E.,
Newmeyer, D. D.,
and Green, D. R.
(1998)
EMBO (Eur. Mol. Biol. Organ.) J.
17,
37-49[CrossRef][Medline]
[Order article via Infotrieve]
22.
Kuida, K.,
Haydar, T. F.,
Kuan, C. Y., Gu, Y.,
Taya, C.,
Karasuyama, H., Su, M. S.,
Rakic, P.,
and Flavell, R. A.
(1998)
Cell
94,
325-337[CrossRef][Medline]
[Order article via Infotrieve]
23.
Hakem, R.,
Hakem, A.,
Duncan, G. S.,
Henderson, J. T.,
Woo, M.,
Soengas, M. S.,
Elia, A.,
de la Pompa, J. L.,
Kagi, D.,
Khoo, W.,
Potter, J.,
Yoshida, R.,
Kaufman, S. A.,
Lowe, S. W.,
Penninger, J. M.,
and Mak, T. W.
(1998)
Cell
94,
339-352[CrossRef][Medline]
[Order article via Infotrieve]
24.
Van Pel, A.,
van der Bruggen, P.,
Coulie, P. G.,
Brichard, V. G.,
Lethe, B.,
van den Eynde, B.,
Uyttenhove, C.,
Renauld, J. C.,
and Boon, T.
(1995)
Immunol. Rev.
145,
229-250[CrossRef][Medline]
[Order article via Infotrieve]
25.
Wilson, K. P.,
Black, J. A.,
Thomson, J. A.,
Kim, E. E.,
Griffith, J. P.,
Navia, M. A.,
Murcko, M. A.,
Chambers, S. P.,
Aldape, R. A.,
Raybuck, S. A.,
and Livingston, D. J.
(1994)
Nature (Lond.)
370,
270-275[CrossRef][Medline]
[Order article via Infotrieve]
26.
Walker, N. P.,
Talanian, R. V.,
Brady, K. D.,
Dang, L. C.,
Bump, N. J.,
Ferenz, C. R.,
Franklin, S.,
Ghayur, T.,
Hackett, M. C.,
and Hammill, L. D.
(1994)
Cell
78,
343-352[CrossRef][Medline]
[Order article via Infotrieve]
27.
Rotonda, J.,
Nicholson, D. W.,
Fazil, K. M.,
Gallant, M.,
Gareau, Y.,
Labelle, M.,
Peterson, E. P.,
Rasper, D. M.,
Ruel, R.,
Vaillancourt, J. P.,
Thornberry, N. A.,
and Becker, J. W.
(1996)
Nat. Struct. Biol.
3,
619-625[CrossRef][Medline]
[Order article via Infotrieve]
28.
Mori, K.
(2000)
Cell
101,
451-454[CrossRef][Medline]
[Order article via Infotrieve]
29.
Chauhan, D.,
Hideshima, T.,
Rosen, S., C., R. J.,
Kharbanda, S.,
and Anderson, K. C.
(2001)
J. Biol. Chem.
276,
24453-24456 30.
Srinivasula, S. M.,
Hegde, R.,
Saleh, A.,
Datta, P.,
Shiozaki, E.,
Chai, J.,
Lee, R. A.,
Robbins, P. D.,
Fernandes-Alnemri, T.,
Shi, Y.,
and Alnemri, E. S.
(2001)
Nature (Lond.)
410,
112-116[CrossRef][Medline]
[Order article via Infotrieve]
31.
Scaffidi, C.,
Fulda, S.,
Srinivasan, A.,
Friesen, C., Li, F.,
Tomasselli, K. J.,
Debatin, K.-M.,
Krammer, P. H.,
and Peter, M. E.
(1998)
EMBO (Eur. Mol. Biol. Organ.) J.
17,
1675-1687[CrossRef][Medline]
[Order article via Infotrieve]
32.
Li, H.,
Zhu, H., Xu, C.-J.,
and Yuan, J.
(1998)
Cell
94,
491-501[CrossRef][Medline]
[Order article via Infotrieve]
33.
Luo, X.,
Budihardjo, I.,
Zou, H.,
Slaughter, C.,
and Wang, X.
(1998)
Cell
94,
481-490[CrossRef][Medline]
[Order article via Infotrieve]
34.
Pinton, P.,
Ferrari, D.,
Rapizzi, E., Di,
Virgillo, F.,
Pozzan, T.,
and Rizzuto, R.
(2001)
EMBO (Eur. Mol. Biol. Organ.) J.
20,
2690-2701[CrossRef][Medline]
[Order article via Infotrieve]
35.
Rao, R. V.,
Castro-Obregon, S.,
Frankowski, H.,
Schuler, M.,
Stoka, V.,
del Rio, G.,
Bredesen, D. E.,
and Ellerby, H. M.
(2002)
J. Biol. Chem.
277,
21836-21842 36.
Lamkanfi, M.,
Declercq, W.,
Kalai, M.,
Saelens, X.,
and Vandenabeele, P.
(2002)
Cell Death Diff.
9,
358-361[CrossRef][Medline]
[Order article via Infotrieve]
37.
Jean, D.,
Harbison, M.,
McConkey, D. J.,
Ronai, Z.,
and Bar-Eli, M.
(1998)
J. Biol. Chem.
273,
24884-24890 38.
Jean, D.,
Tellez, C.,
Huang, S.,
Davis, D. W.,
Bruns, C. J.,
McConkey, D. J.,
Hinrichs, S. H.,
and Bar-Eli, M.
(2000)
Oncogene
19,
2721-2730[CrossRef][Medline]
[Order article via Infotrieve]
39.
Mattson, M. P.,
LaFerla, F. M.,
Chan, S. L.,
Leissring, M. A.,
Shepel, P. N.,
and Geiger, J. D.
(2000)
Trends Neurosci.
23,
222-229[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. Okada, T. Misaka, Y. Tanaka, I. Matsumoto, K. Ishibashi, S. Sasaki, and K. Abe Aquaporin-11 knockout mice and polycystic kidney disease animals share a common mechanism of cyst formation FASEB J, October 1, 2008; 22(10): 3672 - 3684. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Jeong, D.-Y. Lee, S. Park, and S. G. Rhee ERp16, an Endoplasmic Reticulum-resident Thiol-disulfide Oxidoreductase: BIOCHEMICAL PROPERTIES AND ROLE IN APOPTOSIS INDUCED BY ENDOPLASMIC RETICULUM STRESS J. Biol. Chem., September 12, 2008; 283(37): 25557 - 25566. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Y. Fu, T. Minamino, O. Tsukamoto, T. Sawada, M. Asai, H. Kato, Y. Asano, M. Fujita, S. Takashima, M. Hori, et al. Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition Cardiovasc Res, September 1, 2008; 79(4): 600 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Kanungo, Z. Hao, A. J. Elia, T. W. Mak, and J. T. Henderson Inhibition of Apoptosome Activation Protects Injured Motor Neurons from Cell Death J. Biol. Chem., August 8, 2008; 283(32): 22105 - 22112. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sasaya, T. Utsumi, K. Shimoke, H. Nakayama, Y. Matsumura, K. Fukunaga, and T. Ikeuchi Nicotine Suppresses Tunicamycin-Induced, But Not Thapsigargin-Induced, Expression of GRP78 during ER Stress-Mediated Apoptosis in PC12 Cells J. Biochem., August 1, 2008; 144(2): 251 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kitamura Endoplasmic reticulum stress and unfolded protein response in renal pathophysiology: Janus faces Am J Physiol Renal Physiol, August 1, 2008; 295(2): F323 - F334. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. McDonnell, Md. J. Abedin, M. Melendez, T. N. Platikanova, J. R. Ecklund, K. Ahmed, and A. Kelekar Phosphorylation of Murine Caspase-9 by the Protein Kinase Casein Kinase 2 Regulates Its Cleavage by Caspase-8 J. Biol. Chem., July 18, 2008; 283(29): 20149 - 20158. [Abstract] [Full Text] |